Preston Sprenkle, MD, presented “Oral Abstracts – Spacial Characterization and AI-Driven Prevention of Residual Cancer Following Focal Therapy” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 17, 2024, in San Diego, California.
>
How to cite: Sprenkle, Preston. “Oral Abstracts – Spacial Characterization and AI-Driven Prevention of Residual Cancer Following Focal Therapy.” October, 2024. Accessed Jan 2025. https://grandroundsinurology.com/oral-abstracts-spacial-characterization-and-ai-driven-prevention-of-residual-cancer-following-focal-therapy/
Oral Abstracts – Spacial Characterization and AI-Driven Prevention of Residual Cancer Following Focal Therapy – Summary
Substituting for Wayne Brisbane, MD, Preston Sprenkle, MD, highlights the evaluation of AI-driven cancer risk mapping in guiding focal therapy for prostate cancer. This 7-minute presentation shares results related to Unfold AI, a tool cleared by the FDA in December 2022 for generating 3D cancer risk maps.
The primary focus of the presentation is determining whether AI mapping could predict marginal treatment failures. The AI model demonstrated high precision, significantly reducing necessary treatment margins and potentially enhancing patient outcomes while minimizing treatment invasiveness.
Dr. Sprenkle discusses future directions, including the prospective use of AI-defined margins in treatment planning, which could potentially reduce focal therapy failures. This retrospective study underscores the transformative potential of AI in improving prostate cancer treatment precision.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Preston C. Sprenkle, MD, is an Associate Professor of Urology at Yale University School of Medicine in New Haven, Connecticut. He also serves as Director of the Urology Research Fellowship and Urologic Oncology Clinical Fellowship Program at Yale, and as Division Chief of Urology in the VA Connecticut Healthcare System. Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device, and he is also a pioneer in focal therapy. In his practice, Dr. Sprenkle believes in working with patients to come up with individualized treatment plans to minimize the impact of prostate cancer diagnosis and treatment on their health and quality of life. His research focuses on biomarkers for prostate and kidney cancer, including the biomarker NGAL for acute kidney injury in surgical patients.
